CMPXCompass Therapeutics, Inc.

Nasdaq compasstherapeutics.com


$ 1.60 $ 0.01 (0.63 %)    

Friday, 10-May-2024 15:59:25 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 1.6
$ 1.60
$ 0.00 x 0
$ 0.00 x 0
$ 1.50 - $ 1.62
$ 1.15 - $ 3.62
254,288
na
220.14M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 03-15-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-01-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-18-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 04-30-2021 03-31-2021 10-Q
13 03-05-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
16 06-08-2020 03-31-2020 10-K
17 02-14-2020 12-31-2019 10-Q
18 11-13-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 07-01-2019 03-31-2019 10-K
21 02-14-2019 12-31-2018 10-Q
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 compass-therapeutics-receives-fda-fast-track-designation-for-the-investigation-of-ctx-009-in-combination-with-paclitaxel-for-the-treatment-of-patients-with-metastatic-or-locally-advanced-biliary-tract-tumors-that-have-been-previously-treated

CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical respon...

 hc-wainwright--co-reiterates-buy-on-compass-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 ...

 compass-therapeutics-presents-data-demonstrating-elimination-of-mhc-class-i-negative-tumors-in-models-at-2024-aacr-annual-meeting

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resista...

 wedbush-reiterates-outperform-on-compass-therapeutics-maintains-8-price-target

Wedbush analyst Robert Driscoll reiterates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and maintains $8 price target.

 hc-wainwright--co-maintains-buy-on-compass-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 p...

 compass-therapeutics-q4-eps-011-misses-009-estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate o...

 compass-therapeutics-provides-corporate-update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF...

 why-nextgen-healthcare-shares-are-trading-higher-by-13-here-are-20-stocks-moving-premarket

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market trading after gaining around 9% ...

 hc-wainwright--co-reiterates-buy-on-compass-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION